Search results
2 kwi 2024 · Universal vaccination: To reduce community transmission and protect individuals with HIV, this committee agrees with the CDC recommendations for universal vaccination against COVID-19 for adults (≥18 years old) with HIV, regardless of prior history of COVID-19 infection.
The update contains important new guidance regarding the use of new vaccines against human papillomavirus (HPV), shingles (herpes zoster) and pneumococcus. Further key updates are related to the use of hepatitis B, meningococcus and pertussis vaccines.
A 30-year old woman with HIV (CD4+ count 12, VL 140,000) presented for new onset pruritic papules and pustules on the face and ears of three weeks duration. She has been on ART intermittently since her HIV diagnosis two years ago and initiated second-line ART three weeks prior.
1 mar 2024 · One of the most promising attempts to reinvigorate the stalled quest for an HIV vaccine has hit a snag that might seem minor but has major consequences: delaying the larger trials needed to show whether the concept works.
25 kwi 2023 · HPV vaccination may have a relevant impact in settings featured by low HIV prevention coverage, where mathematical models showed that the cumulative number of HIV infections that could be averted by HPV vaccination over 50 years could reach up to 27,812 cases in women and 14,693 cases in men .
19 lip 2024 · Eligible participants were healthy women (assigned female sex at birth) aged 18–35 years who had had sexual intercourse with a male partner two or more times in the 30 days before screening, were at increased risk of acquiring HIV-1, and were HIV-1-negative and HIV-2-negative.
3 lip 2024 · The use of HPV vaccination in persons with HIV is safe and effective, with seroconversion rates of 95% in men 18 years of age and older who received the quadrivalent vaccine and seroconversion rates of 92.3 to 100% among women with HIV aged 16 to 23 years who received the quadrivalent vaccine.
